A drug for treating diabetes similar to popular weight-loss medicines such as Ozempic did not show any benefits for people ...

Scientists remain puzzled as to why some individuals taking popular weight loss and diabetes medications such as Ozempic and ...

Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the ...

Expanded Ozempic approval in the U.S. could transform how doctors treat patients with chronic kidney disease, which involves ...

The Food and Drug Administration on Tuesday approved Ozempic to reduce the risk of serious complications in people who have ...

Popular drugs like Ozemic and Monjauro aid in managing diabetes by lowering blood sugar levels. They have surged in popularity because they hasten weight loss. And this new class of drugs —GLP-1 ...

Nephrologists jumped on the GLP-1 bandwagon well before Novo Nordisk won FDA approval for Ozempic in chronic kidney disease ...

A new study examines how cost, side effects, and other factors influence whether people stop GLP-1s, while Noom cuts staff to ...

Nearly 2 in 3 people who sought to lose weight quit popular weight loss and diabetes drugs such as Ozempic or Victoza within one year, according to a new study. About 65% of those without diabetes ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Surgical patients may still have leftovers in their system even after a standard fast, potentially increasing the chance of a ...

Experts are calling on the government to implement strategies that will better predict future Ozempic shortages.